Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans

Propanc Biopharma (Nasdaq:PPCB) approved a 1-for-25 reverse stock split of its common shares, effective before market open on May 18, 2026.

Rhea-AI Summary

Propanc Biopharma (Nasdaq:PPCB) approved a 1-for-25 reverse stock split of its common shares, effective before market open on May 18, 2026. The split will proportionally reduce outstanding shares, with fractional shares rounded up, and will not change the par value.

The stock will continue trading on Nasdaq under the symbol PPCB with a new CUSIP 74346N800. Propanc states the reverse split is intended to help restore compliance with Nasdaq’s $1.00 minimum bid price and support its growth plans.

Positive

• 1-for-25 reverse stock split designed to help regain Nasdaq $1.00 bid compliance
• Fractional shares rounded up to nearest whole share per shareholder
• Trading symbol PPCB maintained post-split, aiding investor continuity
• Par value of common stock unchanged after reverse split

Negative

• Need to restore compliance with Nasdaq continued listing and $1.00 bid standards signals prior noncompliance risk

Argus May 14 session

-21.40% close to close Open Argus

Details

News Market Reaction – PPCB

In the May 14 session, PPCB declined 21.40%, reflecting a significant negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock dropped -21.4% in the session following this news. A negative reaction despite the corpora...

Analysis

The stock dropped -21.4% in the session following this news. A negative reaction despite the corporate rationale would fit PPCB’s pattern of declines following ostensibly constructive updates. The 1-for-25 reverse split, reduction of outstanding shares to about 2.28M, and focus on Nasdaq’s $1.00 bid standard highlight listing pressure and prior dilution. Investors would need to weigh whether future financings and preclinical-to-clinical execution could further pressure post-split pricing.

Key Figures

Reverse split ratio: 1-for-25 Pre-split shares: 56,959,280 shares Post-split shares: 2,278,372 shares +5 more

Reverse split ratio

1-for-25

Approved March 16, 2026 for common stock

Pre-split shares

56,959,280 shares

Approximate common shares outstanding as of May 6, 2026

Post-split shares

2,278,372 shares

Approximate pro forma common shares after reverse split

Par value

$0.001 per share

Par value of PPCB common stock, unchanged by split

Nasdaq bid minimum

$1.00

Nasdaq minimum bid price requirement referenced for continued listing

Planned trial phase

Phase 1b

Planned first-in-human clinical study for PRP in advanced solid tumors

Effective date

May 18, 2026

Reverse stock split anticipated to be effective before market open

New CUSIP

74346N800

CUSIP for PPCB common stock after reverse split

Historical Context

5 past events · Latest: Mar 24

5 events

1. Mar 24

   Research partnership

   24h Move

   -5.9%

   Multi-year anti-aging and cancer research collaboration with Spanish universities.

2. Mar 12

   Preclinical results

   24h Move

   -13.6%

   Reported >85% tumor inhibition and plans for Phase 1b trials in 2026.

3. Mar 10

   Service agreement

   24h Move

   -20.5%

   Service deal to develop LC-MS PK assay supporting Phase 1b study of PRP.

4. Mar 03

   Pipeline update

   24h Move

   -5.2%

   Detailed PRP preclinical efficacy, orphan status and planned 2026 first-in-human trial.

5. Feb 18

   Corporate update

   24h Move

   -4.5%

   Half-year results, IP expansion plans, and up to $100M private placement facility.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

reverse stock split, par value, nasdaq, cusip, +1 more

5 terms

reverse stock split financial

"approved a 1-for-25 reverse stock split of the Company's issued and outstanding shares"

A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.

par value financial

"shares of common stock, par value $0.001 per share, (the “Reverse Stock Split”)"

Par value is the fixed amount printed on a bond or stock that represents its original value when issued. It’s like the face value of a coin or bill—what the issuer promises to pay back or the starting price of a stock—though it often doesn’t change with market prices. It matters because it helps determine certain financial details, like how much the company will pay back at maturity.

nasdaq regulatory

"restore compliance with the continued listing standards of the Nasdaq Stock Market"

The Nasdaq is a stock exchange where many companies' shares are bought and sold, functioning much like a marketplace for investments. It matters to investors because it provides a platform to buy and sell ownership stakes in companies, helping them track the value of those companies and make informed decisions. As one of the largest and most technology-focused markets, it also reflects trends and developments in the business world.

View in glossary

cusip regulatory

"with a new CUSIP number, 74346N800. Securities Transfer Corporation, the Company’s transfer"

A CUSIP is a nine-character alphanumeric code that uniquely identifies a U.S. or Canadian financial security—such as a stock, bond, or fund share—like a Social Security number for an investment. It matters to investors because brokers, exchanges and record-keepers use the CUSIP to match trades, track ownership, settle transactions and pull accurate records, reducing errors and ensuring money and securities go to the right place.

View in glossary

phase 1b medical

"advances its lead asset, PRP, to a world-first, Phase 1b clinical study in advanced cancer"

"Phase 1b" is an early stage in testing a new medical treatment or vaccine, where it is given to a small group of people to evaluate its safety and determine the right dose. For investors, this phase signals progress in development, indicating the treatment is advancing through initial safety checks, which can influence expectations for future success and potential market impact.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MELBOURNE, Australia , May 13, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced that its Board of Directors on March 16, 2026, approved a 1-for-25 reverse stock split of the Company's issued and outstanding shares of common stock, par value $0.001 per share, (the “Reverse Stock Split”). The Reverse Stock Split is anticipated to be effective as of the open of the market May 18, 2026.

As a result of the Reverse Stock Split, every 25 pre-split shares of Company common stock outstanding will automatically combine into one new share of common stock without any action on the part of the holders, and the number of outstanding common shares will be reduced from approximately 56,959,280 million shares (as of May 6, 2026) to approximately 2,278,372 million shares on a pro forma basis. Fractional shares resulting from the Reverse Stock Split will be rounded up to the nearest whole share on a per shareholder basis (per participant basis at DTC). The Reverse Stock Split will not affect the par value of the Company’s common stock.

The Company anticipates that the effective time of the Reverse Stock Split will be before market open on May 18, 2026, with the common stock trading on a post-split basis under the Company's existing trading symbol, “PPCB,” with a new CUSIP number, 74346N800. Securities Transfer Corporation, the Company’s transfer agent, will act as the exchange agent for the Reverse Stock Split.

“The Reverse Stock Split is being implemented to enable the Company to expeditiously restore compliance with the continued listing standards of the Nasdaq Stock Market and Nasdaq’s $1.00 minimum bid price requirement and growth plans. We look forward to providing further updates as the Company advances its lead asset, PRP, to a world-first, Phase 1b clinical study in advanced cancer patients suffering from solid tumors,” said Mr. James Nathanielsz, Propanc’s Chief Executive Officer.

About Propanc Biopharma, Inc.

Propanc Biopharma, Inc. (Nasdaq: PPCB) is developing a novel approach to preventing cancer recurrence and metastasis by targeting and eradicating cancer stem cells through proenzyme activation. The Company’s lead product candidate, PRP, is designed to address the underlying drivers of cancer proliferation and spread.

More information: www.propanc.com

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to the Company’s expectations regarding its market position and market opportunity, expectations and plans as to its product development, manufacturing and sales, and relations with its partners and investors, made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are not historical facts but rather are based on the Company’s current expectations, estimates, and projections regarding its business, operations and other similar or related factors. Words such as “may,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expect,” “intend,” “plan,” “project,” “believe,” “estimate,” and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond the Company’s control. Forward-looking statements are not guarantees of future actions or performance. Actual results may differ materially from those in the forward-looking statements because of several factors, including, without limitation, risks and uncertainties related to market conditions, as well as those risks described under “Risk Factors” in the prospectus related to the proposed offering and those described in the Company’s filings with the SEC. The Company undertakes no obligation to revise or update information in this release to reflect events or circumstances in the future, even if new information becomes available.

Company:
Propanc Biopharma, Inc.
James Nathanielsz

+61-3-9882-0780

info@propanc.com

Investor Contact:

irteam@propanc.com

FAQ

What is the Propanc Biopharma (PPCB) reverse stock split ratio and effective date?

Propanc Biopharma is implementing a 1-for-25 reverse stock split effective before market open on May 18, 2026. According to Propanc, this corporate action consolidates every 25 existing common shares into one post-split share while preserving the stock’s current par value.

Why is Propanc Biopharma (PPCB) conducting a reverse stock split in May 2026?

Propanc Biopharma states the reverse stock split aims to help restore compliance with Nasdaq’s continued listing standards and $1.00 minimum bid price. According to Propanc, the move also supports its broader growth plans while maintaining access to the Nasdaq Capital Market.

How will the Propanc Biopharma (PPCB) reverse stock split affect existing shareholders?

Each Propanc shareholder will receive one new share for every 25 pre-split shares they own. According to Propanc, outstanding shares will be proportionally reduced, fractional shares rounded up to the nearest whole share, and there will be no change to the par value.

Will Propanc Biopharma’s ticker symbol and CUSIP change after the reverse split?

Propanc Biopharma will keep trading on Nasdaq under the existing ticker symbol PPCB after the reverse split. According to Propanc, only the CUSIP number will change, becoming 74346N800, while Securities Transfer Corporation will act as the exchange agent.

How does the Propanc Biopharma (PPCB) reverse split relate to its cancer drug candidate PRP?

The reverse split is primarily intended to support Nasdaq listing compliance and growth plans. According to Propanc, the company also plans to advance its lead asset PRP into a world-first Phase 1b clinical study in advanced solid tumor cancer patients.